VermaS,PoulterNR,BhattDL,BainSC,BuseJB,LeiterLA,etal.Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: Post hoc analy- sis from the leader trial.Circulation.2018;138:288494, .MannJFE,FonsecaV,MosenzonO,RazI,GoldmanB,IdornT,etal.Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 dia- betes mellitus and chronic kidney disease: Results from the LEADER trial.Circulation.2018;138:290818, VermaS,BhattDL,BainSC,BuseJB,MannJFE,MarsoSP,etal.Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease.Circulation.2018;137:217983, Funding This work was supported by the Instituto de Salud Carlos III (PI19/01375) co-financed with FEDER programme fund
For more content from #AHA23 head to the Late-Breaking or the CardioNerds Conference Scholars Collection
A noticeable decrease in alcohol cravings
Get personalized dose guidance, side-effect management, and medical monitoring so constipation does not become the reason you quit treatment
Your healthcare provider will monitor your blood sugar closely to ensure optimal control
Hmx 1-homeobox transcription factor
